Abstracts Archive - Page 1121 of 2607 - ACR Meeting Abstracts

Abstract Number: 2715 • 2019 ACR/ARP Annual Meeting
Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset
Ruth Costello¹, Janet McDonagh ², Will Dixon ¹, Kimme Hyrich ² and Jenny Humphreys ¹, ¹Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, ²Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom / NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common childhood onset inflammatory arthritis. The last estimates of incidence of this disease in the United Kingdom…
Abstract Number: 2716 • 2019 ACR/ARP Annual Meeting
Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Rebecca Overbury¹, Aimee Hersh ², CJ Inman ², Sara Stern ², Karen James ² and John Bohnsack ³, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: Childhood onset rheumatoid arthritis (CORA) describes patients with juvenile idiopathic arthritis (JIA) who are rheumatoid factor (RF) or anti-cyclic citrullinated antibody (ACPA) positive. Phenotypically,…
Abstract Number: 2717 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of Juvenile-onset Psoriatic Arthritis
Devy Zisman¹, Tal Gazitt ², Amir Haddad ², Idit Lavi ², Snezana Barac ³, Vinod Chandran ⁴, Jan Dutz ⁵, Lihi Eder ⁶, James T Elder ⁷, Richard Hayday ⁸, Proton Rahman ⁹, Christopher Ritchlin ¹⁰, Sherry Rohekar ¹¹, Cheryl F. Rosen ¹² and Dafna Gladman ¹³, ¹Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ²Carmel Hospital, Haifa, Israel, ³Winnipeg Clinic, Winnipeg, MB, Canada, ⁴Department of Medicine, University of Toronto,Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of British Columbia, Vancuver, BC, Canada, ⁶Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁷University of Michigan Medical School,, Ann Arbor, MI, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Memorial University, Newfoundland, NL, Canada, ¹⁰Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ¹¹Western University, London, ON, Canada, ¹²Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: There is no consensus in the literature with regard to the features and long-term prognosis of psoriatic arthritis (PsA) starting in childhood (jPsA). We…
Abstract Number: 2718 • 2019 ACR/ARP Annual Meeting
A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis
Kiana Taba¹ and Elizabeth Ortiz ², ¹University of Southern California, LAGUNA HILLS, CA, ²LAC+USC/Keck Medicine of USC, Los Angeles
Background/Purpose: The use of biologic DMARDs (bDMARDs) has vastly changed the treatment of autoimmune arthritis, both Rheumatoid Arthritis (RA) and polyarticular and oligoarticular Juvenile Idiopathic…
Abstract Number: 2719 • 2019 ACR/ARP Annual Meeting
Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers
Rebecca Sadun¹, Amanda Eudy ¹, Peter Chiraseveenuprapund ², Cuoghi Edens ³, Aimee Hersh ⁴, Kiana Johnson ⁵ and Erica Lawson ⁶, ¹Duke University, Durham, ²UCSD, San Diego, CA, ³University of Chicago, Chicago, IN, ⁴University of Utah, Salt Lake City, UT, ⁵East Tennessee, Johnson City, TN, ⁶University of California San Francisco Benioff Children’s Hospital, San Francisco, CA
Background/Purpose: The transition from pediatric to adult-oriented health care represents a vulnerable period for young adults with chronic rheumatic diseases. In spite of this, a…
Abstract Number: 2720 • 2019 ACR/ARP Annual Meeting
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Rebecca Overbury¹, John Bohnsack ², CJ Inman ³, Sara Stern ³, Karen James ³, Daniel Clegg ³, Tracy Frech ⁴ and Aimee Hersh ³, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah School of Medicine, Salt Lake City, UT, ³University of Utah, Salt Lake City, UT, ⁴Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT
Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…
Abstract Number: 2721 • 2019 ACR/ARP Annual Meeting
Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome
Sabrina Gmuca¹, Maitry Sonagra ², Rui Xiao ², Elizabeth Mendoza ², Kimberly S. Miller ³, Nina H. Thomas ¹, Pamela F. Weiss ¹, David D. Sherry ¹ and Jeffrey Gerber ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³Children's Hospital fo Philadelphia, Philadelphia, PA
Background/Purpose: Dyscognition, including loss of mental clarity and problems with attention and memory, often affects adolescents with juvenile fibromyalgia syndrome (JFMS). Our understanding of this…
Abstract Number: 2722 • 2019 ACR/ARP Annual Meeting
The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes
Jordan Jones¹, Daniel J. Lovell ², Chelsey Smith ³ and Mara Becker ⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ³Children's Mercy Kansas City, Kansas, MO, ⁴Duke Children's Hospital, Durham, NC
Background/Purpose: Down syndrome arthropathy (DA) is under-recognized with a 19-month average delay in diagnosis (1). The majority present with polyarticular, rheumatoid factor (RF) and anti-nuclear…
Abstract Number: 2723 • 2019 ACR/ARP Annual Meeting
Alagille Syndrome and Chronic Arthritis: An International Case Series
Giovanna Ferrara ¹, Teresa Giani¹, Scott M Lieberman ², Sandy Hong ³, Courtney Kremer ³, Giuseppe Indolfi ¹, Grant Schulert ⁴, Randy Cron ⁵, Melissa Mannion ⁶, Sivia Lapidus ⁷, Emmanuel Jacquemin ⁸, Isabelle Kone-Paut ⁹ and Rolando Cimaz ¹⁰, ¹Anna Meyer Children University Hospital, Florence, Italy, ²University of Iowa, Iowa City, Iowa City, ³University of Iowa, Iowa City, Iowa City, IA, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Alabama, ⁷Joseph M. Sanzari Children’s Hospital, Hackensack Meridian Health, New Jersey, ⁸Le Kremlin Bicetre, Paris, France, ⁹Rhumatologie pédiatrique et CEREMAIA,, Université Paris-Sud Saclay, Paris, France, ¹⁰Meyer Children's Hospital in Florence, Florence, Italy
Background/Purpose: Alagille syndrome is a complex multisystem disease characterized by chronic cholestasis due to a paucity of intrahepatic bile ducts, congenital heart disease and ocular…
Abstract Number: 2724 • 2019 ACR/ARP Annual Meeting
Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA
Alexander Solyom¹, Erik Sundberg ², John Mitchell ³, Christina Grant ⁴, Carlos Ferreira ⁵, Paul Harmatz ⁶, Neslihan Mungan ⁷, Fatma Bulut ⁷, Christina Lampe ⁸, Andreas Hahn ⁸, Norberto Guelbert ⁹, Nur Arslan ¹⁰, Balahan Makay ¹⁰, Ratna Puri ¹¹, Sunita Bijarnia-Mahay ¹¹, Laila Selim ¹², Iman Gamal el Din ¹², Seema Kapoor ¹³, Maja DiRocco ¹⁴, Seza Ozen ¹⁵, Ezgi Batu ¹⁵, Gulden Gokcay ¹⁶, Marta Torcoletti ¹⁷, Alan Kimura ¹⁸ and Bo Magnusson ², ¹Enzyvant, Basel, Switzerland, ²Karolinska University Hospital, Stockholm, Sweden, ³Montreal Children's Hospital, Montreal, Canada, ⁴Children's National Medical Center, Washingotn, DC, ⁵Children's National Medical Center, Washington, DC, ⁶UCSF Benioff Children's Hospital Oakland, Oakland, CA, ⁷Cukurova University Hospital, Adana, Turkey, ⁸University Hospital Giessen, Giessen, Germany, ⁹Children's Hospital of Cordoba, Cordoba, Argentina, ¹⁰Dokuz Eylul University Hospital, Izmir, Turkey, ¹¹Sir Ganga Ram Hospital, Delhi, India, ¹²Cairo University Children's Hospital, Cairo, Egypt, ¹³13Lok Nayak Hospital and Maulana Azad Medical College, Delhi, India, ¹⁴Istituto Giannina Gaslini, Genoa, Italy, ¹⁵Hacettepe University Hospital, Ankara, Turkey, ¹⁶Istanbul University, Istanbul, Turkey, ¹⁷University of Milan, Milan, Italy, ¹⁸Enzyvant, Cambridge, MA
Background/Purpose: The cardinal clinical symptoms of Farber disease (arthritis/contractures, subcutaneous granulomatous nodules, dysphonia) may be misdiagnosed as JIA. Mutations in the ASAH1 gene and the…
Abstract Number: 2725 • 2019 ACR/ARP Annual Meeting
Clinical Factors Distinguishing Between Pediatric Tumors with Arthritis at Onset and JIA: Preliminary Analysis of the ONCOREUM Study
Adele Civino¹, Gianni Alighieri ², Roberto Rondelli ³, Silvia Magni-Manzoni ⁴, Micol Romano ⁵, Giovanni Filocamo ⁶, Francesca Santarelli ⁷, Francesca Ricci ⁸, Alma Nunzia Olivieri ⁹, Serena Pastore ¹⁰, Patrizia Barone ¹¹, Romina Gallizzi ¹², Angela Miniaci ¹³, Manuela Marsili ¹⁴, Rosanna Podda ¹⁵, Bianca Lattanzi ¹⁶, Maria Cristina Maggio ¹⁷, Rita Consolini ¹⁸, Francesco La Torre ¹⁹, Maria Antonietta Pelagatti ²⁰, Francesca Soscia ²¹, Alessandro De Fanti ²², Donato Rigante ²³, Eleonora Prete ²⁴, Giulia Stabile ²⁵, Andrea Roncadori ²⁶, Loredana Lepore ²⁷, Valentino Conter ²⁸, Andrea Pession ²⁹ and Angelo Ravelli ³⁰, ¹Pediatric Rheumatology “Vito Fazzi” Hospital, Lecce, Lecce, Italy, ²Pediatric Unit “Card. G. Panico” Hospital, Tricase, Tricase, Italy, ³Department of Pediatrics, "Lalla Seragnoli" , Hematology - Oncology Unit , University of Bologna, Bologna, ⁴Rheumatology, Bambino Gesù Children's Hospital, IRCCS, Rome, Roma, ⁵Division of Rheumatology, ASST Gaetano Pini, Milan, Milano, ⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Milano, Italy, ⁷Pediatric Immunology and Rheumatology, "Regina Margherita" Children Hospital, University of Turin, Torino, Italy, ⁸Pediatric Clinic, Asst Spedali Civili, University of Brescia, Brescia, Italy, ⁹Pediatric Rheumatology, Second University of Studies of Naples, Napoli, Italy, ¹⁰Pediatric Rheumatology, IRCCS Burlo Garofolo, Trieste, Italy;, Trieste, Italy, ¹¹Department of Pediatrics, University of Catania, Catania, Italy, Catania, Italy, ¹²Azienda Ospedaliera Universitaria Gaetano Martino, Messina, Messina, Italy, ¹³Department of Pediatrics, "Lalla Seragnoli" , Rheumatology , University of Bologna, Bologna, Italy, ¹⁴Pediatric Rheumatology, University of Chieti, Chieti, Italy, ¹⁵Paediatric Rheumatology, Ospedale Pediatrico Microcitemico A. Cao, Cagliari, Cagliari, Italy, ¹⁶Pediatric Rheumatology, Ospedali Riuniti di Ancona, Ancona, Italy, ¹⁷Department of Health Promotion Sciences Maternal and Infantile Care, “G. D’Alessandro”, University of Palermo, Palermo, Italy, ¹⁸Department of clinical and experimental Medicine University of Pisa, Pisa, Italy, ¹⁹Rheumatology Section. Pediatric Unit. Giovanni XXIII Pediatric Hospital. Bari, Bari, Italy, ²⁰Paediatric Rheumatology, MBBM Foundation, San Gerardo Hospital Monza, Monza, Italy, ²¹Pediatric Unit Santa Maria della Stella Hospital, Orvieto, Orvieto, Italy, ²²Pediatric and Adolescent Rheumatology Unit Azienda USL-IRCCS, Reggio Emilia, Reggio Emilia, Italy, ²³Institute of Pediatrics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Roma, Italy, ²⁴Department of Hematology and Bone Marrow Trasplant Card. G. Panico” Hospital, Tricase, Tricase, Italy, ²⁵Inter-University Consortium Cineca, Casalecchio di Reno (BO), Casalecchio di Reno, ²⁶Inter-University Consortium Cineca, Casalecchio di Reno (BO), Casalecchio di Reno, Italy, ²⁷Pediatric Rheumatology, IRCCS Burlo Garofolo, Trieste, Trieste, Italy, ²⁸Paediatric Haemato-Oncology, University of Milano-Bicocca, MBBM Foundation, Monza, Monza, Italy, ²⁹Department of Pediatrics, "Lalla Seragnoli" , Hematology - Oncology Unit , University of Bologna, Bologna, Italy, ³⁰Pediatric Rheumatology, IRCCS Giannina Gaslini Institute Genova, Genova, Italy
Background/Purpose: Musculoskeletal (MSK) symptoms are a common presenting complaint in pediatric primary care (estimated prevalence 25-50%) and may be the initial manifestation of cancer in…
Abstract Number: 2726 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics and Quality of Life Metrics in Non-Infectious Uveitis
Jessica Shantha¹, Amy Cassedy ², Joseph McDonald ³, Theresa Hennard ⁴, Najima Mwase ⁵, Steven Yeh ¹ and Sheila Angeles-Han ⁶, ¹Emory University, Atlanta, GA, ²Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati
Background/Purpose: Uveitis is a heterogenous group of ocular inflammatory diseases. Underlying disease and treatment can lead to poor quality of life (QOL), depression, and increased…
Abstract Number: 2727 • 2019 ACR/ARP Annual Meeting
Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Bhargavi Duvvuri¹, Lauren Pachman ², Richard Moore ¹, Gabrielle Morgan ², Marisa Klein-Gitelman ², Megan L. Curran ³, Stephen Doty ⁴ and Christian Lood ¹, ¹University of Washington, Seattle, ²Northwestern University, Chicago, ³University of Colorado, Aurora, CO, ⁴Hospital for Special Surgery, New York
Background/Purpose: Though mainly found intracellularly, we recently observed mitochondrial extrusion upon cell death, contributing to inflammation and organ damage in lupus-prone mice. Of note, mitochondria…
Abstract Number: 2728 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
Désirée van der Heijde¹, In-Ho Song ², Aileen Pangan ³, Atul Deodhar ⁴, Filip Van den Bosch ⁵, Walter P. Maksymowych ⁶, Tae-Hwan Kim ⁷, Mitsumasa Kishimoto ⁸, Andrea Everding ⁹, Yunxia Sui ¹⁰, Xin Wang ¹⁰, Alvina D. Chu ¹⁰ and Joachim Sieper ¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Oregon Health & Science University, Portland, OR, ⁵Ghent University Hospital, Ghent, Belgium, ⁶University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁹HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ¹⁰AbbVie Inc., Chicago, ¹¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) who have an inadequate response/contraindication to NSAIDs have limited treatment options other than biologics. The Janus kinase (JAK)…
Abstract Number: 2729 • 2019 ACR/ARP Annual Meeting
Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
Atul Deodhar¹, Désirée van der Heijde ², Lianne Gensler ³, Tae-Hwan Kim ⁴, Walter P. Maksymowych ⁵, Mikkel Østergaard ⁶, Denis Poddubnyy ⁷, Helena Marzo-Ortega ⁸, Louis Bessette ⁹, Tetsuya Tomita ¹⁰, Gaia Gallo ¹¹, David Adams ¹¹, Ann Leung ¹², Fangyi Zhao ¹¹, Maja Hojnik ¹¹, Hilde Carlier ¹³ and Joachim Sieper ¹⁴, ¹Oregon Health & Science University, Portland, OR, ²Leiden University Medical Center, Leiden, Netherlands, ³University San Francisco California, San Francisco, CA, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁸NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ⁹Laval University, Quebec City, QC, Canada, ¹⁰Osaka University Graduate School of Medicine, Osaka, Japan, ¹¹Eli Lilly and Company, Indianapolis, IN, ¹²Syneos Health, Raleigh, NC, ¹³Eli Lilly and Company, Indianapolis, ¹⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Ixekizumab (IXE), a high affinity IL-17A monoclonal antibody, previously showed efficacy in AS/radiographic-axSpA1,2. COAST-X (NCT02757352) is a phase 3 study that assessed efficacy and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].